Bioresistant devices are desirable in applications where limiting biological reactions to implants is beneficial to patient outcomes.

Tissue integration into some permanent implants could lead to impaired function. Surgeons seek to limit tissue ingrowth into spine and joint arthroplasties, for example, a leading failure mode following such procedures. The Orthobond bioresistant technology can address these issues by limiting soft-tissue adhesion.

Bioresistant materials could also create a protein-resistant surface that would limit platelet aggregation or soft tissue integration, thus avoiding early occlusion of stents or grafts. This could help to prevent thrombosis in patients with coronary stents, thus reducing postoperative morbidity.

Additionally, bioresistant catheters, shunts, and biliary stents with diminished adhesion of biomolecules provide the benefits of reducing early occlusion and possible device failure. Additionally, B-SAMP-treated materials could afford easier removal of implants.

For more information, download our white paper on B-SAMP.